InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,883.60
(
-0.59%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.57
(
-2.71%
)
Bitcoin
57,327.06
(
-5.40%
)
Post# of 251666
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 214130

Saturday, 10/07/2017 2:38:20 AM

Saturday, October 07, 2017 2:38:20 AM

Post# of 251666
Re Quiz
When MedImmune (AZN subsidiary) has in-licensed tremelimumab back in 2011, Pfizer has retained the rights to use tremelimumab with specified types of combination therapies. In the study you cited, It is given to some patients as part of a possible regimen, with the vax booster (plasmid DNA) in hope that an anti CTLA-4 will further increase the immune response of the vaccine.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up